Another set of write-downs. Still carrying way too much Goodwill for the Nexstellis donkey - this is turning out to be worse than Genetics and we are still in the early days...
Disappointing read - but *finally* believable - less sugar more salt!
The books show clearly why no-one was interested in the business outside of MCS. None of it is standing up on it's own. Need more information about what happened with Dermology - someone dodging the dodge on revenue reporting??? New board - new standards and it was found out. Drop seems way to big for stocktaking error.
Too much spend to give away - no-one would want it; but really need the D2D campaign for Nexstellis to continue to gather steam and the marketing expenses to drop... A $44m EBITDA loss on fk all sales is going to destroy this company quickly. Bye-Bye $100m left over from the MCS sale WHAT A WASTE
Nexstellis team need to continue to work on their relationship with Health Care providers. Big feedback is that after the $25 a month introductory, people are facing a cost of over $100 (US!) to continue as not every health provider is subsidising.
Capital Return and reverse split will be interesting now as with these results and the weakness in SP - there will be people just holding on for that $cash, then without positive news; tank time.
MYX Price at posting:
21.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
WHAT A WASTE
(20min delay)